This site is intended for healthcare professionals

2625 pages added, reviewed or updated during the last month (last updated: 15/4/2021)

2625 pages added, reviewed or updated during the last month (last updated: 15/4/2021)


Medical search

ciclesonide

FREE subscriptions for doctors and students... click here
You have 3 more open access pages.

  • ciclesonide is a once daily, inhaled corticosteroid delivered via a hydrofluoroalkane (non-CFC) metered-dose inhaler, licensed for the prophylactic treatment of persistent asthma in adults
  • is converted to the active metabolite in the lungs and has low systemic bioavailability, therefore it has a lower potential for systemic adverse effects
  • in short term studies ciclesonide caused less suppression of cortisol release compared with budesonide or fluticasone, but there is no evidence that this translates into fewer long-term (>52 weeks) adverse effects
  • evidence indicates that it is of equivalent efficacy to existing inhaled steroids (budesonide and fluticasone) in the management of mild-to-moderate asthma, but long-term data on clinical outcomes such as exacerbations, hospitalisations and quality of life are unavailable
  • promoted for its relative lack of local adverse effects, and convenience to the patient (once-daily administration). It may help patients who do not comply with regular inhaled corticosteroid therapy
  • not licensed to use in children under the age of 12 years (2)

Reference:

Last reviewed 01/2018

Links: